A citation-based method for searching scientific literature

Henry L Paulson, Vikram G Shakkottai, H Brent Clark, Harry T Orr. Nat Rev Neurosci 2017
Times Cited: 145



Tetsuo Ashizawa, Gülin Öz, Henry L Paulson. Nat Rev Neurol 2018
Times Cited: 89




List of shared articles



Times cited


Antisense Oligonucleotide Therapy Targeted Against ATXN3 Improves Potassium Channel-Mediated Purkinje Neuron Dysfunction in Spinocerebellar Ataxia Type 3.
David D Bushart, Annie J Zalon, Hongjiu Zhang, Logan M Morrison, Yuanfang Guan, Henry L Paulson, Vikram G Shakkottai, Hayley S McLoughlin. Cerebellum 2021
6


Human stem cell models of polyglutamine diseases: Sources for disease models and cell therapy.
Lang He, Zhao Chen, Linliu Peng, Beisha Tang, Hong Jiang. Exp Neurol 2021
4

Current Status of Gene Therapy Research in Polyglutamine Spinocerebellar Ataxias.
Ricardo Afonso-Reis, Inês T Afonso, Clévio Nóbrega. Int J Mol Sci 2021
4

Spinocerebellar ataxia clinical trials: opportunities and challenges.
Sarah M Brooker, Chandrakanth Reddy Edamakanti, Sara M Akasha, Sheng-Han Kuo, Puneet Opal. Ann Clin Transl Neurol 2021
3

Clinical and genetic profile in index patients with spinocerebellar ataxia type 3 in Indonesia: case report.
Siti Aminah, Fathul Huda, Uni Gamayani, Iin Pusparini, Mochammad Faisal Afif Mochyadin, Yunia Sribudiani, Norlinah Mohamed Ibrahim, Tri Hanggono Achmad. Heliyon 2021
0

CRISPR/Cas9 mediated gene correction ameliorates abnormal phenotypes in spinocerebellar ataxia type 3 patient-derived induced pluripotent stem cells.
Lang He, Shang Wang, Linliu Peng, Huifang Zhao, Shuai Li, Xiaobo Han, Jean de Dieu Habimana, Zhao Chen, Chunrong Wang, Yun Peng,[...]. Transl Psychiatry 2021
2

Polyglutamine Ataxias: Our Current Molecular Understanding and What the Future Holds for Antisense Therapies.
Craig S McIntosh, Dunhui Li, Steve D Wilton, May T Aung-Htut. Biomedicines 2021
0

Update on intensive motor training in spinocerebellar ataxia: time to move a step forward?
Giuseppe Lanza, Jacopo Antonino Casabona, Maria Bellomo, Mariagiovanna Cantone, Francesco Fisicaro, Rita Bella, Giovanni Pennisi, Placido Bramanti, Manuela Pennisi, Alessia Bramanti. J Int Med Res 2020
10

Pathogenesis of SCA3 and implications for other polyglutamine diseases.
Hayley S McLoughlin, Lauren R Moore, Henry L Paulson. Neurobiol Dis 2020
46

Neurochemical profiles in hereditary ataxias: A meta-analysis of Magnetic Resonance Spectroscopy studies.
Janna Krahe, Ferdinand Binkofski, Jörg B Schulz, Kathrin Reetz, Sandro Romanzetti. Neurosci Biobehav Rev 2020
10

Universal RNAi Triggers for the Specific Inhibition of Mutant Huntingtin, Atrophin-1, Ataxin-3, and Ataxin-7 Expression.
Anna Kotowska-Zimmer, Yuliya Ostrovska, Marta Olejniczak. Mol Ther Nucleic Acids 2020
11

Small heat shock proteins in neurodegenerative diseases.
Leen Vendredy, Elias Adriaenssens, Vincent Timmerman. Cell Stress Chaperones 2020
16

In Vivo Molecular Signatures of Cerebellar Pathology in Spinocerebellar Ataxia Type 3.
Maria do Carmo Costa, Maria Radzwion, Hayley S McLoughlin, Naila S Ashraf, Svetlana Fischer, Vikram G Shakkottai, Patrícia Maciel, Henry L Paulson, Gülin Öz. Mov Disord 2020
6

Natural history and epidemiology of the spinocerebellar ataxias: Insights from the first description to nowadays.
Stephanie Suzanne de Oliveira Scott, José Luiz Pedroso, Orlando Graziani Povoas Barsottini, Marcondes Cavalcante França-Junior, Pedro Braga-Neto. J Neurol Sci 2020
3

Polyglutamine spinocerebellar ataxias: emerging therapeutic targets.
Andreia Neves-Carvalho, Sara Duarte-Silva, Andreia Teixeira-Castro, Patrícia Maciel. Expert Opin Ther Targets 2020
3

Clinical Characteristics and Possible Drug Targets in Autosomal Dominant Spinocerebellar Ataxias.
Laszlo Szpisjak, Denes Zadori, Peter Klivenyi, Laszlo Vecsei. CNS Neurol Disord Drug Targets 2019
4